Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
An updated panel of 578 barcoded cancer cell lines were used to profile the activity of 4518 existing drugs with a diversity of indications. An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines. Results were used to begin the PRISM drug repurposing resource (depmap.org/repurposing).
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines
First publication of the PRISM method from 2016. 102 cell lines were labeled with unique 24-nucleotide barcodes and used to screen 8400 compounds. BRD-7880 was identified as a potent and highly specific inhibitor of aurora kinases B and C.
